A specific therapy to treat EA1 and epilepsy phenotypes caused by KCNA1 mutations is lacking and pharmacological technologies targeting Kv1.1 channels would be ideal to overcome the limits of available therapeutic options and to offer patients a personalized therapy. This evidence concerns the gene KCNA1 and epilepsy.